- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04264455
Evaluation of Long-term Incidence of Ventricular Arrhythmias in Patients With Acute Myocarditis (AIM-ICD)
Myocarditis is an inflammatory disease of the heart muscle which is mostly caused by viruses, bacteria, parasites, toxic substances/drugs or by primary autoimmune mechanisms. Signs of heart failure (dyspnea, reduced resilience, tendency to edema), thoracic pain, palpitations / arrhythmias / syncope, as well as (potentially) lethal clinical conditions in the sense of a cardiogenic shock or sudden cardiac death can be found.
In 2015, the European Society of Cardiology (ESC) gave a IIa recommendation for the indication of an ICD vest restoration as "bridging" until the acute phase subsides (possibly normalisation of the left ventricular pump function with reduced probability of malignant cardiac arrhythmia) or until ICD implantation in cases of severe LV dysfunction and/or ventricular electrical instability. The Monitoring and analysis of malignant cardiac arrhythmias are therefore crucial in the treatment of acute myocarditis.
The aim of this study is to observe the long-term incidence of ventricular arrhythmias in patients diagnosed with myocarditis and to analyze the MRI and echocardiographic data obtained as potential predictive factors for the occurrence of ventricular arrhythmias.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Myocarditis is an inflammatory disease of the heart muscle, which is mostly caused by viruses, bacteria, parasites, toxic substances/drugs or by primary autoimmune mechanisms. In the first phase of acute myocarditis direct cell damage, in a second phase myocardial inflammation with additional myocardial damage can be observed. Symptoms vary widely and may include signs of heart failure (dyspnoea, reduced exercise capacity, edema tendency), chest pain, palpitations / arrhythmias / syncope, and (potentially) lethal clinical conditions such as cardiogenic shock or sudden cardiac death. Predictors of increased mortality are syncopes, malignant arrhythmias EF≤35% or heart failure NYHA III-IV. ICD implantation is recommended <3 months after manifestation only in exceptional situations (e.g. following resuscitation). The European Society of Cardiology (ESC) issued a IIa recommendation in 2015 for the indication of ICD vest fitting as "bridging" until the acute phase subsides (possible normalization of left ventricular pumping function with reduced probability of malignant cardiac arrhythmias) or until ICD implantation in cases of severe LV dysfunction and/or ventricular electrical instability is necessary. The observation, monitoring and analysis of malignant cardiac arrhythmias are therefore crucial in the treatment of acute myocarditis.
The aim of this study is to observe the long-term incidence of ventricular arrhythmias in patients with diagnosed myocarditis and to analyze the MRI and echocardiographic data obtained as potential predictive factors for the occurrence of ventricular arrhythmias.
The study is a prospective multicenter registry study. All potentially stressful measures and examinations such as blood sampling and echocardiography - except for follow-up MRI examinations - are carried out at our centre as standard clinical progress assessment, even independently of participation in the registry. The indication for biomonitor implantation is given after initial screening by means of a 24h-LZ-ECG with positive results (detection of ventricular arrhythmias). The registry study is performed with approved IECDs (Implantable electronic cardiovascular devices: Biomonitor (BioMonitor 2-AF, BioMonitor 3-AF (after release)), Biotronik® ICD) as well as WCD (Wearable Cardioverter Defibrillator, Zoll® LifeVest) and Biotronik® Cardio Messenger. The implantation is carried out exclusively according to the indication/testing guidelines. Thus, there are no risks or disadvantages for the participating patient.
The primary aim of the study is to monitor the long-term incidence of ventricular arrhythmias in patients with diagnosed myocarditis and to identify potential predictive factors for their occurrence.
Secondary goal is to analyze the long-term survival and need for heart transplantation and to identify MRI/echocardiographic parameters as determinants of arrhythmias.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Christina Moser
- Phone Number: 0049 (0) 931 201 39946
- Email: moser_c@ukw.de
Study Locations
-
-
Bayern
-
Würzburg, Bayern, Germany, 97080
- Recruiting
- Wuerzburg University Hospital
-
Contact:
- Christina Moser
- Phone Number: 004993120139946
- Email: moser_c@ukw.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- secured myocarditis via MRT / endomyocardial biopsy
- ventricular arrhythmias (≥ 5 beats) in the ECG / LZ ECG with clinical indication for a WCD system/ biomonitor/ or the indication for primary/secondary prophylactic ICD implantation
- presence of informed consent
- age >18 and <85 years
Exclusion Criteria:
- Participation in another study with an active treatment group
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Biomonitor only
Patients receive a Biomonitor only
|
Patients receive a Biomonitor only
Patients receive an Implantable Cardioverter-Defibrillator (ICD)
|
Wearable Cardioverter-Defibrillator (Life Vest) + Biomonitor
Patients receive a Wearable Cardioverter-Defibrillator (Life Vest) combined with a Biomonitor
|
Patients receive a Biomonitor only
Patients receive an Implantable Cardioverter-Defibrillator (ICD)
Patients receive a Wearable Cardioverter-Defibrillator; a Biomonitor is implanted additionally
|
ICD Implantation
Patients receive an ICD only
|
Patients receive an Implantable Cardioverter-Defibrillator (ICD)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Monitoring the change of long-term incidence of ventricular arrhythmias in patients with acute myocarditis at several follow-up dates.
Time Frame: 24 months follow-up
|
The primary aim of the study is to monitor the long-term incidence of ventricular arrhythmias and/or sudden cardiac death in patients with diagnosed myocarditis and identify potential predictive factors for their occurrence. The 2-years incidence of sudden cardiac death and ventricular arrhythmias acquired by the respective device holters in use is investigated. |
24 months follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter Nordbeck, MD, PhD, University Hospital Wuerzburg
- Principal Investigator: Jonas Muentze, MD, University Hospital Wuerzburg
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IT-II-2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Arrythmia
-
University Hospital, MontpellierCompletedRight Ventricular Dysfunction | Ventricular ArrythmiaFrance
-
AtaCor Medical, Inc.CompletedVentricular Fibrillation | Ventricular Tachycardia | Ventricular ArrythmiaParaguay
-
University of LuebeckInstitute for Robotics and Cognitive Systems, University of LuebeckNot yet recruiting
-
Rush University Medical CenterMedical University of South Carolina; University of Michigan; The Cleveland Clinic and other collaboratorsNot yet recruitingCardiomyopathies | Ventricular Tachycardia | Ventricular ArrythmiaUnited States
-
The Leeds Teaching Hospitals NHS TrustUnknownArrythmiaUnited Kingdom
-
Western Sydney Local Health DistrictNational Heart Foundation, Australia; University of SydneyNot yet recruitingArrhythmias, Cardiac | Cardiomyopathies | Ventricular Tachycardia | Ventricular Arrythmia
-
Universitätsklinikum KölnNot yet recruitingVentricular Tachycardia | Ventricular Arrythmia | End-stage Heart Failure | LVAD (Left Ventricular Assist Device)
-
MicroPort CRMActive, not recruitingHeart Failure | Ventricular Arrythmia | ICD | LeadSpain, Portugal
-
Catheter Precision. Inc.Not yet recruitingVentricular Tachycardia | Ventricular Arrythmia | Premature Ventricular Contraction
-
Won Young KimRecruitingCardiac Arrest | Ventricular ArrythmiaKorea, Republic of
Clinical Trials on Biomonitor
-
Biotronik SE & Co. KGCompletedSyncope | Atrial Fibrillation (AF) | Cryptogenic Stroke | TachyarrhythmiaSpain, Australia, Germany, Switzerland, Austria, Denmark
-
Biotronik SE & Co. KGCompleted
-
Biotronik SE & Co. KGIHF GmbH - Institut für Herzinfarktforschung; Qmed Consulting A/SCompletedMyocardial Infarction | Myocardial Infarction Old | Myocardial Infarction, AcuteSpain, Denmark, United States, Germany, Latvia, Australia, Czechia, Belgium, France, Austria, Hungary, Netherlands, Poland, Slovakia
-
Sheba Medical CenterUnknown
-
Biotronik SE & Co. KGCompletedAtrial Fibrillation | Syncope | Tachyarrhythmia
-
Biotronik SE & Co. KGCompleted
-
Mayo ClinicCompletedTTR Cardiac AmyloidosisUnited States
-
Biotronik, Inc.CompletedInsertable Cardiac MonitorUnited States
-
Fundación EPICActive, not recruitingHeart Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Syncope | TachycardiaSpain
-
University Hospital, CaenHospices Civils de Lyon; Centre Hospitalier Universitaire de Saint Etienne; Saint... and other collaboratorsNot yet recruitingAtrial FibrillationFrance